Corin and Furin: Two Enzymes That Could Change How We Diagnose Heart Failure | Research

The takeaway

The enzymes corin and furin activate natriuretic peptides critical for heart health, and their disruption contributes to heart failure progression.

Modest sensitivity and specificity
Corin and furin biomarker performance currently trails established markers like BNP and NT-proBNP for heart failure diagnosis

What the researchers found

Corin and furin show altered expression across different heart failure phenotypes, offering mechanistic insight into disease progression, though their diagnostic performance remains modest compared to BNP and NT-proBNP.

Why it matters

Understanding the upstream enzymes that activate protective heart peptides could lead to new diagnostic tools and targeted therapies for heart failure, moving beyond current one-size-fits-all approaches.

The numbers in context

Reviews corin (cardiac-restricted serine protease) and furin (ubiquitous convertase). Both activate pro-ANP and pro-BNP. Diagnostic performance shows modest sensitivity and specificity compared to BNP/NT-proBNP.

How the study worked

Narrative review synthesizing published studies on the physiological and pathological roles of corin and furin in heart failure, evaluating their biomarker potential.

Who was studied

Heart failure patients (conceptual review)

What this study cannot tell us

Corin and furin biomarker performance has not yet shown clear incremental benefit over existing markers in clinical settings. Most evidence is from observational studies, not prospective clinical trials.

How to read the evidence

This is a narrative review of existing literature. While it provides valuable mechanistic insights, the clinical utility of corin and furin as biomarkers has not been validated in large prospective trials.

When this study was published

Published in 2025, incorporating the latest research on natriuretic peptide pathway enzymes in heart failure.

The bigger picture

This work points toward a future where heart failure diagnosis goes beyond measuring end-product peptides to understanding the enzymatic machinery behind them, potentially enabling earlier detection and personalized treatment.

Questions still open

Can corin and furin levels predict heart failure subtypes better than current biomarkers when used in combination panels?
Could therapies directly targeting the corin-furin axis restore natriuretic peptide activation in heart failure patients?

Common questions

What do corin and furin do in the heart?

Corin and furin are enzymes that activate natriuretic peptides — hormones released by the heart to regulate blood pressure, fluid balance, and neurohormonal signaling. When these enzymes malfunction, the protective peptides cannot be properly activated, contributing to heart failure.

Could corin and furin replace BNP tests for heart failure?

Not currently. Their diagnostic performance is modest compared to BNP and NT-proBNP. However, they may eventually serve as complementary biomarkers that provide mechanistic insight into what is driving heart failure in individual patients.

Read the original research

Beyond Natriuretic Peptides: Corin and Furin As Phenotype-Specific Biomarkers and Therapeutic Gatekeepers in Heart Failure.

Current heart failure reports, 22(1), 41

View on PubMed ↗Publisher’s paper ↗

Citation

Patel, Dhruvil Vinaybhai; Patel, Sanket; Acharya, Sankalp; Raol, Karanrajsinh. (2025). Beyond Natriuretic Peptides: Corin and Furin As Phenotype-Specific Biomarkers and Therapeutic Gatekeepers in Heart Failure.. Current heart failure reports, 22(1), 41. https://doi.org/10.1007/s11897-025-00732-x